Cell Proliferation Receptor-Enhanced 3D High-Throughput Screening Model for Optimized Drug Efficacy Evaluation in Breast Cancer Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang-Yun | - |
dc.contributor.author | Hwang, Hyun Ju | - |
dc.contributor.author | Ku, Bosung | - |
dc.contributor.author | Lee, Dong Woo | - |
dc.date.accessioned | 2022-10-28T02:40:21Z | - |
dc.date.available | 2022-10-28T02:40:21Z | - |
dc.date.created | 2022-10-28 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 0003-2700 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85879 | - |
dc.description.abstract | A higher correlation of epidermal growth factor receptor (EGFR)-targeting drugs has been reported with the use of the cell proliferation receptor-enhanced three-dimensional high-throughput screening model (CPRE 3D-HTS model) compared with two-dimensional (2D) cell-based HTS. A greater expression of differential human EGFR 2 (HER2) protein between HER2-positive and HER2-negative cell lines was observed in breast cancer (BC) cell lines cultured using the CPRE 3D-HTS model compared with 2D-cultured cells. When using 2D-cultured cells, properties such as the expression of the cell proliferation receptor are lost as the cells attach to the bottom of the well plate. In an effort to solve this problem, the CPRE 3D-HTS model expressing high cell proliferation receptors was optimized by the selection of alginate as the extracellular matrix. Results from the use of the CPRE 3D-HTS model showed higher drug resistance with increased expression of drug resistance-related proteins. Of particular interest, a higher correlation of HER2-targeted drugs was observed with the use of the CPRE 3D-HTS model. In order to validate this higher correlation of target drugs observed in the CPRE 3D-HTS model, the results of Western blot analysis and high content imaging analysis were analyzed, which confirmed that 3D-cultured BC cell lines showed a greater difference in the expression of HER2-positive and HER2-negative BC cell lines than 2D-cultured cells. Thus, the use of CPRE 3D-HTS using a 384-pillar plate resulted in increased accuracy when screening HER2-targeted drugs in BC, and it is a very useful platform for analyzing the efficacy of targeted drugs by enhancing the expression of HER2. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.relation.isPartOf | ANALYTICAL CHEMISTRY | - |
dc.title | Cell Proliferation Receptor-Enhanced 3D High-Throughput Screening Model for Optimized Drug Efficacy Evaluation in Breast Cancer Cells | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000855058000001 | - |
dc.identifier.doi | 10.1021/acs.analchem.2c02222 | - |
dc.identifier.bibliographicCitation | ANALYTICAL CHEMISTRY, v.94, no.34, pp.11838 - 11847 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85136522295 | - |
dc.citation.endPage | 11847 | - |
dc.citation.startPage | 11838 | - |
dc.citation.title | ANALYTICAL CHEMISTRY | - |
dc.citation.volume | 94 | - |
dc.citation.number | 34 | - |
dc.contributor.affiliatedAuthor | Lee, Sang-Yun | - |
dc.contributor.affiliatedAuthor | Lee, Dong Woo | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | HER2 EXPRESSION | - |
dc.subject.keywordPlus | CULTURE | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | 2D | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.